Assessment of 123I-mIBG and 99mTc-tetrofosmin single-photon emission computed tomographic images for the prediction of arrhythmic events in patients with ischemic heart failure: Intermediate severity innervation defects are associated with higher arrhythmic risk

Journal of Nuclear Cardiology

Volumn 24, Issue 2, 2017, Pages 377-391

  Travin, Mark I ^a   Henzlova, Milena J ^b   van Eck Smit, Berthe L F ^c   Jain, Diwakar ^d   Carrió, Ignasi ^e   Folks, Russell D ^f   Garcia, Ernest V ^f   Jacobson, Arnold F ^g,h   Verberne, Hein J ^c  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b MOUNT SINAI MEDICAL CENTER   (United States)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

^d WESTCHESTER MEDICAL CENTER   (United States)

^e UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^f EMORY UNIVERSITY HOSPITAL   (United States)

^g Diagram Consulting   (United States)

^h GE HEALTHCARE   (United States)

Author keywords

123I mIBG; arrhythmias; heart failure; SPECT

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; BRAIN NATRIURETIC PEPTIDE; NORADRENALIN; TETROFOSMIN TC 99M; (3 IODOBENZYL)GUANIDINE; ORGANOPHOSPHORUS COMPOUND; RADIOPHARMACEUTICAL AGENT; TECHNETIUM COMPLEX; TECHNETIUM TC-99M TETROFOSMIN;

ADULT; ANGINA PECTORIS; ARTICLE; CARDIAC IMAGING; DISEASE SEVERITY; FEMALE; FOLLOW UP; HEART ARRHYTHMIA; HEART DEATH; HEART FAILURE; HEART INFARCTION; HEART INNERVATION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART MUSCLE ISCHEMIA; HEART VENTRICLE ARRHYTHMIA; HIGH RISK PATIENT; HUMAN; IMAGE RECONSTRUCTION; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MIDDLE AGED; NEW YORK HEART ASSOCIATION CLASS; NORADRENALIN BLOOD LEVEL; PREDICTION; PRIORITY JOURNAL; SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY; CAUSALITY; CLINICAL TRIAL; COMORBIDITY; COMPARATIVE STUDY; DIAGNOSTIC IMAGING; EVALUATION STUDY; INCIDENCE; INTERNATIONAL COOPERATION; MORTALITY; MULTICENTER STUDY; PROCEDURES; PROGNOSIS; REPRODUCIBILITY; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY-COMPUTED TOMOGRAPHY; STATISTICS AND NUMERICAL DATA; SURVIVAL RATE;

3-IODOBENZYLGUANIDINE; ARRHYTHMIAS, CARDIAC; CAUSALITY; COMORBIDITY; FEMALE; HEART FAILURE; HUMANS; INCIDENCE; INTERNATIONALITY; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; ORGANOPHOSPHORUS COMPOUNDS; ORGANOTECHNETIUM COMPOUNDS; PROGNOSIS; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; RISK FACTORS; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY COMPUTED TOMOGRAPHY; SURVIVAL RATE;

EID: 84954534275     PISSN: 10713581     EISSN: 15326551     Source Type: Journal    
DOI: 10.1007/s12350-015-0336-8     Document Type: Article

References (33)

1. Merlet P, Valette H, Dubois-Randé J, Moyse D, Duboc D, Dove P, et al. Prognostic value of cardiac metaiodobenzylguanidine in patients with heart failure. J Nucl Med 1992;33:471-7.
2. Nakata T, Miyamoto K, Doi A, Sasao H, Wakabayashi T, Kobayashi H, et al. Cardiac death prediction and impaired cardiac sympathetic innervation assessed by MIBG in patients with failing and nonfailing hearts. J Nucl Cardiol 1998;5:579-90.
3. Agostini D, Verberne HJ, Burchert W, Knuuti J, Povinec P, Sambuceti G, et al. I-123-mIBG myocardial imaging for assessment of risk for a major cardiac event in heart failure patients: Insights from a retrospective European multicenter study. Eur J Nucl Med Mol Imaging 2008;35:535-46.
4. Verberne HJ, Brewster LM, Somsen GA, van Eck-Smit BL. Prognostic value of myocardial 123I-metaiodobenzylguanidine (MIBG) parameters in patients with heart failure: A systematic review. Eur Heart J 2008;29:1147-59.
5. Jacobson AF, Senior R, Cerqueira MD, Wong ND, Thomas GS, Lopez VA, et al. Myocardial iodine-123 meta-iodobenzylguanidine imaging and cardiac events in heart failure. Results of the prospective ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) study. J Am Coll Cardiol 2010;55:2212-21.
6. Nakata T, Nakajima K, Yamashina S, Yamada T, Momose M, Kasama S, et al. A pooled analysis of multicenter cohort studies of I-123-mIBG cardiac sympathetic innervation imaging for assessment of long-term prognosis in chronic heart failure. JACC Cardiovasc Imaging 2013;6:772-84.
7. Arora R, Ferrick KJ, Nakata T, Kaplan RC, Rozengarten M, Latif F, et al. I-123 MIBG imaging and heart rate variability analysis to predict the needs for an implantable cardioverter defibrillator. J Nucl Cardiol 2003;10:121-31.
8. Tamaki S, Yamada T, Okuyama Y, Morita T, Sanada S, Tsukamoto Y, et al. Cardiac iodine-123 Metaiodobenzylguanidine imaging predicts sudden cardiac death independently of left ventricular ejection fraction in patients with chronic heart failure and left ventricular systolic dysfunction: Results from a comparative study with signal-averaged electrocardiogram, heart rate variability, and QT dispersion. J Am Coll Cardiol 2009;53:426-35.
9. Nagahara D, Nakata T, Hashimoto A, Kyuma M, Noda R, Shimoshige S, et al. Predicting the need for an implantable cardioverter defibrillator using cardiac metaiodobenzylguanidine activity together with plasma natriuretic peptide concentration or left ventricular function. J Nucl Med 2008;49:225-33.
10. Inoue H, Zipes DP. Results of sympathetic denervation in the canine heart: Supersensitivity that may be arrhythmogenic. Circulation 1987;75:877-87.
11. Minardo JD, Tuli MM, Mock BH, Weiner RE, Pride HP, Wellman HN, et al. Scintigraphic and electrophysiologic evidence of canine myocardial sympathetic denervation and reinnervation produced by myocardial infarction or phenol application. Circulation 1988;78:1008-19.
12. Simões MV, Barthel P, Matsunari I, Nekolla SG, Schömig A, Schwaiger M, et al. Presence of sympathetically denervated but viable myocardium and its electrophysiologic correlates after early revascularised, acute myocardial infarction. Eur Heart J 2004;25:551-7.
13. Sasano T, Abraham R, Chang KC, Ashikaga H, Mills KJ, Holt DP, et al. Abnormal sympathetic innervation of viable myocardium and the substrate of ventricular tachycardia after myocardial infarction. J Am Coll Cardiol 2008;51:2266-75.
14. Mitrani RD, Klein LS, Miles WM, Hackett FK, Burt RW, Wellman HN, et al. Regional cardiac sympathetic denervation in patients with ventricular tachycardia in the absence of coronary artery disease. J Am Coll Cardiol 1993;22:1344-53.
15. Paul M, Schäfers M, Kies P, Tayfun A, Schäfers K, Breithardt G, et al. Impact of sympathetic innervation on recurrent life-threatening arrhythmias in the follow-up of patients with idiopathic ventricular fibrillation. Eur J Nucl Med Mol Imaging 2006;33:866-70.
16. 123I-mIBG Scintigraphy to predict inducibility of ventricular arrhythmias on cardiac electrophysiology testing: A prospective multicenter pilot study. Circ Cardiovasc Imaging 2008;1:131-40.
17. Boogers MJ, Borleffs CJ, Henneman MM, van Bommel RJ, van Ramshorst J, Boersma E, et al. Cardiac sympathetic denervation assessed with 123-Iodine metaiodobenzylguanidine imaging predicts ventricular arrhythmias in implantable cardioverter-defibrillator patients. J Am Coll Cardiol 2010;55:2769-77.
18. Marshall A, Cheetham A, George RS, Mason M, Kelion AD. Cardiac iodine-123 metaiodobenzylguanidine imaging predicts ventricular arrhythmia in heart failure patients receiving an implantable cardioverter-defibrillator for primary prevention. Heart 2012;98:1359-65.
19. McGhie AI, Corbett JR, Akers MS, Kulkarni P, Sills MN, Kremers M, et al. Regional cardiac adrenergic function using I-123 Meta-Iodobenzylguanidine tomographic imaging after acute myocardial infarction. Am J Cardiol 1991;67:236-42.
20. Stanton MS, Tuli MM, Radtke NL, Heger JJ, Miles WM, Mock BH, et al. Regional sympathetic denervation after myocardial infarction in humans detected noninvasively using I-123-metaiodobenzylguanidine. J Am Coll Cardiol 1989;14:1519-26.
21. 123I-mIBG scintigraphy to predict risk for adverse cardiac outcomes in heart failure patients: Design of two prospective multicenter international trials. J Nucl Cardiol 2009;16:113-21.
22. Chen J, Garcia EV, Galt JR, Folks RD, Carrió I. Optimized acquisition and processing protocols for I-123 cardiac SPECT imaging. J Nucl Cardiol 2006;13:251-60.
23. 123I-mIBG in older subjects without coronary heart disease. J Nucl Cardiol 2013;20:406-14.
24. Garcia EV, Faber TL, Cooke D, Folks RD, Chen J, Santana C. The increasing role of quantification in clinical nuclear cardiology: The Emory approach. J Nucl Cardiol 2007;14:420-32.
25. Holly TA, Abbott BG, Al-Mallah M, Calnon DA, Cohen MC, DiFilippo FP, et al. Single photon-emission computed tomography. J Nucl Cardiol 2010;17:941-73.
26. 123I-MIBG imaging for prediction of mortality and potentially fatal events in heart failure: The ADMIRE-HFX Study. J Nucl Med 2015;56:1011-8.
27. Shah AM, Bourgoun M, Narula J, Jacobson AF, Solomon SD. Influence of Ejection Fraction on the Prognostic Value of Sympathetic Innervation Imaging with Iodine-123 MIBG in Heart Failure. J Am Coll Cardiol Imaging 2012;5:1139-46.
28. Hosmer DW, Lemeshow S. Applied Logistic Regression. 2nd ed. New York, NY: Wiley; 2000. p. 116-28.
29. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986;1:307-10.
30. Zipes DP, Wellens HJ. Sudden cardiac death. Circulation 1998;98:2334-51.
31. 123I-mIBG imaging. Semin Nucl Med 2011;41:374-87.
32. Fallavollita JA, Heavey BM, Luisi AJ Jr, Michalek SM, Baldwa S, Mashtare TL, et al. Regional myocardial sympathetic denervation predicts the risk of sudden cardiac arrest in ischemic cardiomyopathy. J Am Coll Cardiol 2014;63:141-9.
33. Wakabayashi T, Nakata T, Hashimoto A, Yuda S, Tsuchihashi K, Travin MI, et al. Assessment of underlying etiology and cardiac sympathetic innervation assessment to identify patients at a high-risk of cardiac death. J Nucl Med 2001;42:1757-67.